Alzheimer's drug appears to slow progression in clinical trial but raises safety concerns

November 30, 2022

Alzheimer's drug appears to slow progression in clinical trial but raises safety concerns
By
The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.